Icatibant - Shire

Drug Profile

Icatibant - Shire

Alternative Names: Firazyr; HOE-140; Icatibant; Icatibant acetate; JE-049; SHP-667

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Jerini; sanofi-aventis; Shire
  • Class Kinins; Neuropeptides; Oligopeptides
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Capillary leak syndrome; Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Preregistration Submission Withdrawal Angioedema
  • No development reported Capillary leak syndrome; Liver cirrhosis
  • Discontinued Arrhythmias; Musculoskeletal pain; Myocardial infarction; Pancreatitis; Rhinitis

Most Recent Events

  • 26 Oct 2017 Registered for Hereditary angioedema (In adolescents, In children) in European Union (SC)
  • 01 Oct 2017 Registered for Hereditary angioedema in Japan (SC) prior to October 2017 (Shire pipeline, October 2017)
  • 14 Sep 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of icatibant for Hereditary angioedema (In adolescents, In children) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top